Please login to the form below

Not currently logged in
Email:
Password:

BMS launches global academic collaboration in immuno-oncology

US and European institutes to help translational research into cell-based immunotherapies

Bristol-Myers Squibb (BMS) is to team up with ten cancer institutes and universities from across the world to research how a body's own immune system can fight cancer.

The International Immuno-Oncology Network (II-ON) will take a translational focus to quickly develop scientific research findings, including drug discoveries, into clinical trials then clinical practice.

Dr Elliot Sigal, chief scientific officer and president, R&D, at BMS said the partnership would “leverage intellectual capabilities across a global network,” with partners coming from France, Spain, the US, the UK, Italy and the Netherlands.

He continued: “The shared commitment of all those participating in this collaboration is to evolve our understanding of immuno-oncology towards our ultimate goal of improving patient outcomes.”

The idea of using cell-based immunotherapy to target cancer has been around since the late 1980s, although its only in recent years that its results have come to fruition, including BMS' own antibodies Yervoy (ipilimumab) for skin cancer and Erbitux (cetuximab) for metastatic colorectal cancer and head and neck cancer.

The new partnership will develop the principles behind these medicines even further, with research covering a variety of cancer types.

The involved European institutes are: Clinica Universidad Navarra of Spain; Institut Gustave Roussy of France; the Royal Marsden NHS Foundation Trust of the UK; the UK's Institute of Cancer Research; the Istituto Nazionale per lo Studio e la Cura dei Tumori of Italy; and the Netherlands Cancer Institute.

In the US, BMS will be working with Dana-Farber Cancer Institute, Boston; Johns Hopkins Kimmel Cancer Center, Baltimore; Memorial Sloan-Kettering Cancer Center, New York; and the University of Chicago.

30th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics